The existing, obsolete highpurity water generation system and water-forinjection generation system were replaced with new, reliable technologies.
GlaxoSmithKline (GSK)’s R&D Biopharmaceutical Pilot Plant in Upper Merion, PA is a R&D clinical trial material (CTM) manufacturing facility with an aggressive processing schedule that requires minimal shutdown interruptions. Utility reliability is paramount to achieve production demands and regulatory quality requirements.
To meet the utility demands for increased CTM output, a capital investment project was required to replace the existing, obsolete high purity water (HPW) generation system and water-for-injection (WFI) generation system with new, reliable technology.
This article describes how the new systems were designed and installed in a challenging space to ensure redundancy and improve sustainability.
Download
Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.